Castle Biosciences (CSTL)
(Delayed Data from NSDQ)
$31.63 USD
+5.64 (21.70%)
Updated Nov 4, 2025 04:00 PM ET
After-Market: $31.66 +0.03 (0.09%) 5:26 PM ET
3-Hold of 5 3
D Value A Growth F Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CSTL 31.63 +5.64(21.70%)
Will CSTL be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for CSTL based on the 1-3 month trading system that more than doubles the S&P 500.

Zacks News for CSTL
TG Therapeutics (TGTX) Earnings Expected to Grow: Should You Buy?
Analysts Estimate Castle Biosciences, Inc. (CSTL) to Report a Decline in Earnings: What to Look Out for
CSTL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for CSTL
CSTL: Analyst Baird Raises Price Target on Castle Biosciences | CSTL Stock News
Castle Biosciences price target raised to $41 from $39 at Baird
Castle Biosciences price target raised by $2 at Baird, here's why
Analysts Have Conflicting Sentiments on These Healthcare Companies: Sarepta Therapeutics (SRPT), Castle Biosciences (CSTL) and Viridian Therapeutics (VRDN)
Pocket Pivot appears for CSTL after 1.92% move